Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412

Joseph D. Growney(Novartis (Switzerland)), D. Gary Gilliland(Novartis (Switzerland))
Blood
March 25, 2005
Cited by 250


Related Papers